LogicBio Therapeutics, Inc. (LOGC) Financial Statements (2023 and Earlier)

Company Profile

Business Address 65 HAYDEN AVE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments53,480 50,64780,906
Cash and cash equivalents53,480 33,10780,906
Short-term investments  17,540 
Restricted cash and investments  146 
Receivables30   
Other undisclosed current assets2,156 2,0451,268
Total current assets:55,666 52,83882,174
Noncurrent Assets
Operating lease, right-of-use asset4,571 504
Property, plant and equipment1,911 1,696590
Restricted cash and investments622 622146
Total noncurrent assets:7,104 2,822736
TOTAL ASSETS:62,770 55,66082,910
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,422 3,5632,685
Accounts payable718 6241,168
Accrued liabilities3,704 2,9391,517
Deferred revenue10,639  
Debt3,295   
Other undisclosed current liabilities1,227   
Total current liabilities:19,583 3,5632,685
Noncurrent Liabilities
Long-term debt and lease obligation8,731 9,810 
Long-term debt, excluding current maturities5,006 9,810 
Operating lease, liability3,725  
Liabilities, other than long-term debt3,729   
Deferred revenue3,729  
Total noncurrent liabilities:12,460 9,810 
Total liabilities:32,043 13,3732,685
Stockholders' equity
Stockholders' equity attributable to parent30,727 42,28780,225
Common stock3 33
Additional paid in capital170,744 109,640107,473
Accumulated other comprehensive income (loss)  14(9)
Accumulated deficit(140,020) (67,370)(27,242)
Total stockholders' equity:30,727 42,28780,225
TOTAL LIABILITIES AND EQUITY:62,770 55,66082,910

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues5,410   
Gross profit:5,410   
Operating expenses(44,395) (41,041)(17,943)
Operating loss:(38,985) (41,041)(17,943)
Nonoperating income (expense)(1,072) 935408
Other nonoperating expense(18) (19)(159)
Interest and debt expense(1,070) (546) 
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes  546(86)
Loss from continuing operations before equity method investments, income taxes:(41,127) (40,106)(17,621)
Other undisclosed income from continuing operations before income taxes1,070  86
Loss from continuing operations before income taxes:(40,057) (40,106)(17,535)
Income tax expense (benefit)28 (22)(86)
Net loss available to common stockholders, diluted:(40,029) (40,128)(17,621)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(40,029) (40,128)(17,621)
Comprehensive loss:(40,029) (40,128)(17,621)
Other undisclosed comprehensive income, net of tax, attributable to parent  235
Comprehensive loss, net of tax, attributable to parent:(40,029) (40,105)(17,616)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: